Search Within

Principal Biostatisticians

  1. "David Straus"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (7)
Groups
  1. Center for Hematologic Malignancies (18)
  2. Department of Medicine (18)
  3. Epidemiology and Biostatistics (18)
  4. Hematologic Malignancies, Division of (18)
  5. Lymphoma (18)
  6. Hematology-Oncology Fellows (15)

More Groups

People
  1. David Straus (18)
  2. Esther Drill (18)
  3. Alison Moskowitz (15)
  4. Ariela Noy (15)
  5. Steven Horwitz (15)
  6. Andrew Zelenetz (14)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (2)
  4. 2021 (7)
  5. 2020 (2)
  6. 2019 (5)
Publications
  1. Blood (9)
  2. Journal of Clinical Oncology (3)
  3. Blood Advances (2)
  4. Hematological Oncology (2)
  5. Clinical Lymphoma, Myeloma and Leukemia (1)
  6. Haematologica (1)
Publishers
  1. American Society of Hematology (11)
  2. American Society of Clinical Oncology (3)
  3. Wiley Blackwell (2)
  4. Elsevier Inc. (1)
  5. Ferrata Storti Foundation (1)

Results (18)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
    Journal Article

    Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • IVAC with or without rituximab for relapsed or refractory B-cell non-Hodgkin lymphomas: Real-world experience in the modern era
    Journal Article

    Buege, M. J.; Dao, P. H.; Drill, E.; LeVoir, A.; Pak, T.; Peterson, T. J.; Straus, D. J.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save